Objective. To determine the responsiveness and minimal important change (MIC) of Evaluation of Ankylosing Spondylitis Quality of Life (EASi-QoL), a reliable and valid patient-reported measure of AS-specific quality of life with four domains: physical function (PF), disease activity (DA), emotional well-being (EWB) and social participation (SP).
Introduction
AS is an incurable, inflammatory disease that mainly affects the pelvis and spine [1] and can have a profound impact on health status and quality of life (QoL) [2, 3] . The Assessment of Spondyloarthritis International Society (ASAS) has defined five core assessment domains: functional ability, spinal mobility, pain, spinal stiffness and global assessment [4, 5] . Although QoL was acknowledged as an important concept, it was not included as a core domain, due to uncertainty over measurement selection [4, 5] . Three AS-specific measures of QoL have subsequently been published: the ASQoL questionnaire [6] , the Patient Generated Index AS (PGI-AS) [7] and the Evaluation of Ankylosing Spondylitis Quality of Life (EASi-QoL) questionnaire [8] .
The ASQoL [6] is an 18-item standardized measure. However, several areas frequently nominated by patients as important aspects of AS-related QoL are not included, raising concerns over its content validity [7] . The ASQoL yes/no response scales may be limited in their acceptability to patients [9] , prevent detailed descriptions of health [10, 11] and may contribute to lower levels of responsiveness to small, but clinically important changes in health [12] . The PGI-AS [7] is an individualized measure with good face and content validity, but the individualized format limits its use in clinical trials. The EASi-QoL involved a large number of UK-based patients in item generation and subsequent evaluation, and was developed in response to the above concerns relating to existing AS-specific measures [13] . It has 20 items and measures the impact of AS across four important QoL domains: physical function (PF), disease activity (DA), emotional well-being (EWB) and social participation (SP). It has evidence for good data quality, internal reliability, testretest reliability and content and construct validity following completion by a wide spectrum of UK-based patients [8] .
To be useful in clinical practice or trials, a measure should also be able to reflect any important changes in the health of an individual [14] . This article describes an evaluation of the responsiveness of the EASi-QoL to an improvement in AS health with normal disease variation in an observational cohort. The minimal important change (MIC) of the EASi-QoL is also calculated in this patient group. Responsiveness of the EASi-QoL in AS patients receiving therapeutic interventions was also evaluated following participation in a randomized drug trial [15] .
Methods

Study 1: observational cohort study
The EASi-QoL was evaluated in a postal survey of 1000 patients with AS fulfilling the modified New York criteria for AS [16] , randomly selected from existing databases of 10 secondary care rheumatology centres reflecting a diverse socioeconomic and demographic profile across the UK [17, 18] . Exclusion criteria included pregnancy, learning difficulties and those with English literacy or comprehension difficulties. The survey included the EASi-QoL, disease-specific, domain-specific and generic health measures. Measures were selected that are widely used within rheumatology [13] and for generic measures within outcome measurement more generally [19] . The observational multi-centre cohort was approved by the North Staffordshire Local Research Ethics Committee and 10 centre-specific National Health Service (NHS) trusts in the UK. Written informed consent was obtained according to the Declaration of Helsinki.
The disease-specific measures included the BASDAI [20] , the Bath AS Functional Index (BASFI) [21] and the ASQoL [6] . The domain-specific Hospital Anxiety and Depression Scale (HADS) assesses EWB [22] . Generic measures included the Short Form 36-item Health Survey (SF-36) version 2 [23] . The SF-36 is a measure of health status that provides scores across eight health domains: physical functioning, role limitations due to physical problems, bodily pain, general health, vitality, social functioning, mental health and role limitations due to emotional problems.
Non-responders were sent reminders at 2 and 4 weeks. For purposes of assessing responsiveness, responders were sent the same questionnaire at 6 months, which also included a health transition question (Compared with 6-months ago, how would you rate your AS now?) with five response options: much better, somewhat better, about the same, somewhat worse and much worse.
Study 2: randomized controlled trial
The EASi-QoL was also evaluated in a subgroup of patients from the UK participating in a double-blind study of patients fulfilling the modified New York criteria for AS [16] and randomized to etanercept (ETN) 50 mg once weekly or SSZ up to 3 g daily [15] . Patients had active AS with a BASDAI 5 3/10, morning stiffness 5 30 min and a VAS score over 30/100 for two out of three of the following: patient global assessment of disease activity, pain and BASFI despite treatment with NSAIDs for at least 3 months. Main exclusion criteria were complete ankylosis of the spine and previous treatment with ETN and SSZ within 6 months of screening. Patients completed a questionnaire that included the EASi-QoL, BASDAI, BASFI, SF-36, HADS and ASQoL at baseline and 9 months. The double-blind randomized trial of ETN and SSZ (NCT00247962) received independent ethics committee, institutional review board and regulatory review and approval. Informed consent was obtained according to the Declaration of Helsinki.
Responsiveness analysis
Although several effect size (ES) statistics exist that can be used to communicate the responsiveness of a measure [24, 25] , a recent review suggests that Cohen's ES, calculated as the mean change in score divided by the S.D. at baseline, is the most appropriate [24] . ES statistics were therefore calculated to inform an assessment of the comparative responsiveness of the EASi-QoL against disease-specific, domain-specific or generic measures reflecting similar health domains: EASi-QoL PF was compared with the BASFI and SF-36 PF domain; EASi-QoL DA was compared with the BASDAI; EASi-QoL EWB was compared with the HADS and the SF-36 mental health domain and EASI-QoL SP was compared with the SF-36 social functioning domain. All EASi-QoL domains were compared with the ASQoL.
In the observational cohort study (Study 1), measurement responsiveness was assessed in patients selfreporting an improvement in their AS-specific health at 6 months on the health transition question. Two groups of patients were defined: first, patients who indicated that their health was somewhat better or much better; secondly, patients who indicated that their health was somewhat better only, representing those in whom change may be small but still clinically important. In Study 2, responsiveness was assessed for all patients.
An ES of 0.5 is equivalent to half a baseline S.D. Proposed interpretation guidance suggests a score of 50.8 represents a high level of responsiveness, a score of 0.5 a moderate level of responsiveness and a score of 40.2 a low level of responsiveness [24] .
MIC
Determination of the MIC in Study 1 was based on a method developed previously within back pain [25] and neck pain [26] . The percentage change from baseline on each of the four EASi-QoL domains most associated with improvement was derived using a receiver operating characteristic (ROC) curve with the AS-specific health transition question as the anchor. Those rating their AS as somewhat better or much better were compared with those rating it as unchanged. Participants who scored zero at baseline were excluded, as they cannot, by definition, improve. ROC curves plot sensitivity against 1 À specificity, with sensitivity defined as the number of patients with a particular percentage change in score on the domain and who rated their AS as better divided by all patients stating their AS was better. The percentage change score on each domain for which sensitivity was closest to specificity was taken as the optimal percentage change score. Those who had improved by the defined MIC were then compared with those defined as not having improved (no change or worse) on their change scores on the comparator measures.
Results
Study 1: observational cohort study
Demographics and response rates
Six hundred and twelve (64%) patients returned a completed postal questionnaire; 470 (77%) of these returned questionnaires at 6 months. Baseline characteristics are given in Table 1 . Those who responded to follow-up were slightly older than those who did not (mean age 52 vs 47 years, P < 0.001) with resultant differences also in disease duration. The only other difference was in mental health, with those responding at 6 months having slightly better scores on the HADS-anxiety (mean 7.2 vs 8.2, P = 0.03) and the SF-36 mental health (mean 66 vs 62, P = 0.03) scales. There was no difference on any other demographic, disease-specific or generic measures including use of anti-TNF.
Responsiveness
Eighty (17%) patients reported their AS health as better at 6 months, including 48 (10%) who reported it as somewhat better. Two hundred and seventy-four (58%) reported it as being the same, 115 (25%) as worse and 1 did not complete the item. There was a significant (P < 0.001) linear trend in mean change scores across these three groups for all four EASi-QoL domains (Table 2) .
For all improvers, the ESs for the four EASi-QoL domains ranged from 0.32 (PF) to 0.72 (DA) ( Table 3 ). The EASi-QoL DA domain had an ES of 0.470.72, in comparison with 0.400.58 for the BASDAI. The EASi-QoL SP domain has an ES of 0.300.52 in comparison to lower levels for the SF-36 social functioning domain. Lower www.rheumatology.oxfordjournals.org levels of responsiveness were found for the EASi-QoL EWB and PF domains, respectively, but these were greater than those for the other instruments. With the exception of the EASi-QoL PF domain, the EASI-QoL had higher ESs than the ASQoL index score. For those patients reporting only moderate improvement in AS-specific health ('somewhat better'), ES statistics for all measures were smaller, but followed a similar pattern of comparison (Table 3) . ES statistics for the EASi-QoL ranged from 0.14 (PF) to 0.47 (DA)
MIC
The MIC for the EASi-QoL domains was defined as a change of 10% from baseline for the PF domain (sensitivity 66%, specificity 63%); a change of 20% from baseline for the DA domain (sensitivity 70%, specificity 71%); a change of 15% for the EWB domain (sensitivity 62%, specificity 61%) and a change of 25% for the SP domain (sensitivity 67%, specificity 67%).
The 10% MIC for the EASi-QoL PF domain (score 024) relates to a change score of 1 for scores of 410 at baseline, 2 for scores of 1120 and 3 for scores of 2124. The 20% MIC for the EASi-QoL DA domain (score 016) relates to a change of 1 point for those scores of 45 at baseline, 2 points for scores of 610, 3 points for scores of 1115 and 4 points for scores of 16. The 15% MIC for the EASi-QoL EWB domain (score 020) relates to a change of 1 point for scores 46 at baseline, 2 points for scores 713 and 3 points for scores 1420. The 25% MIC for the EASi-QoL SP domain (score 020) relates to a change of 1 point for scores of 44 at baseline, 2 points for scores 58, 3 points for scores 912, 4 points for scores 1316 and 5 points for scores 1720.
All 470 responders who exceeded the MIC on a domain had significantly (all P < 0.001) higher mean change scores on all comparator measures than those whose percentage change was below the derived MIC (Table 4) . Overall, 299 (64%) participants improved on at least one domain, 167 (36%) on at least two domains and 37 (8%) on all four domains. Study 2: randomized controlled trial Twenty-eight of 29 patients on ETN and 15 of 19 patients on SZP completed all questionnaires at both baseline and 9 months. In the ETN treatment group, each of the four EASi-QoL domains showed good responsiveness to ETN treatment (ES range 1.32.9). The comparator measures also showed good responsiveness of a similar or lower level than the EASi-QoL domains ( Table 5 ). The EASiQoL domains were also generally superior to the overall ASQoL score with the exception of EWB. The limited number of respondents in the SZP group may be detrimental to the robustness of the responsiveness data in this subgroup. However, all EASi-QoL domains in this subgroup showed good responsiveness (lowest was EWB at 0.79). Although the BASDAI and BASFI had better levels of responsiveness than comparator EASi-QoL domains, all measures achieved ES values >0.37. The SF-36 subscales were less responsive. The HADS responsiveness was mixed, with the depression scale showing lower responsiveness than the anxiety scale.
Discussion
In their initial recommendations, ASAS did not recommend QoL as a core assessment domain due to uncertainty over the existing questionnaires [4, 5] . The EASi-QoL was developed to capture experiences of AS considered important by people with AS (for example, body image, mobility and employment) and that were inadequately assessed by existing measures [11] . Patients made a substantial contribution to EASi-QoL development, which has good evidence of acceptability, reliability and validity in a large, UK-wide population of AS patients.
To be useful in routine practice or trials, a measure should be able to identify and reflect important changes in an individual's health. This study compared the responsiveness of the EASi-QoL with other measures commonly used to evaluate AS patients in clinical and trial settings. It evaluates how well these measures reflect improvement in patients, both with normal variation in disease activity (observational cohort study) and in patients participating in a DMARD/ biologic trial. It also defines the MIC in EASi-QoL score following improvement in AS-specific health, thus supporting score interpretation.
Pain, stiffness and physical function dominate current AS core assessment [35] , despite the everyday impact of AS being across a much wider range of physical, psychological and social domains of health [2, 10, 2731] . The Patient Reported Outcome Measure Information System (PROMIS) initiative defined five constructs within a framework for measuring general health: physical function, SP, emotional distress, pain and fatigue [32] , all of which are captured within the EASi-QoL questionnaire.
As expected, the levels of responsiveness reflected in the calculation of ES, seen in the cohort showing improvement with normal fluctuations in disease are lower than those showing improvement after DMARD/biologic treatment; the amount of improvement seen with normal disease fluctuations is less than the improvement of disease with new medication. In the observational study, all EASi-QoL domains had greater or similar levels of responsiveness to their comparator measures. This was the case for patients who reported larger or smaller levels of improvement in AS-specific health, with the larger levels of responsiveness found in the former grouping. With the exception of the BASDAI, all additional comparator measures had low levels of responsiveness in the patient group who reported smaller improvements in health. This result suggests that the EASi-QoL can detect small but potentially clinically important improvements in AS-specific health. Each item in the EASi-QoL includes a five-point descriptive response scale that allows patients to be more discriminative in their responses. This discrimination increases the likelihood that a measure can capture small but important changes in AS-specific health, and hence demonstrate better levels of responsiveness. This is reflected in low levels of responsiveness found for the ASQoL, which has simple yes/no response options, in the group of patients reporting small improvements in health. The ability to measure small improvements in health is of particular importance in AS, where a number of previous studies [3335] assessing non-biologic drug interventions have failed to reach significance, despite widespread existing clinical opinion that these interventions appear to be of benefit in clinical practice.
The main elements of improvement with normal variation in AS do appear to be around the DA and SP domains, with less change seen in the PF or EWB domains. This reflects the clinical impression that pain, stiffness and the effects of these on a patient's life change more quickly and are more influenced by flares of disease than function or mood.
With the exception of the SF-36 social functioning and mental health domains and the HADS-anxiety scale, the EASi-QoL domains, disease-specific and generic comparator domains all had high levels of responsiveness following ETN treatment. As expected, disease-specific measures had greater levels of responsiveness when compared with the generic measures [24] , but comparable levels of responsiveness were found for the EASi-QoL domains and comparative disease-specific measures. Levels of responsiveness were much greater for those EASi-QoL domains (SP and EWB) compared with generic measures.
The smaller improvements seen following SSZ treatment compared with the ETN treatment resulted in lower levels of responsiveness in the SSZ group. With the exception of the SF-36 social functioning domain and the HADS-depression scale, the EASi-QoL domains, disease-specific and generic comparator domains all had high levels of responsiveness following SSZ treatment. Although the highest levels of responsiveness were found for the BASDAI and BASFI, high levels were also found for the EASi-QoL DA and EASi-QoL PF domains, respectively. However, the size of the SSZ group is small (n = 15) and may have led to a spurious result; further evaluation of the relative responsiveness of BASDAI, BASFI and EASi-QoL in a larger, similar cohort is justified. Three EASi-QoL domains (DA, SP, PF) had greater levels of responsiveness when compared with the ASQoL index score, which was comparable to the EASi-Qol EWB domain.
Score interpretation following calculation of the MIC for the EASi-QoL domains suggests generally small changes in score, but it is evident that those reporting better health only had a small amount of change on all measures. Whilst this level of change may not exceed the derived measurement error of the questionnaire, MICs based on measurement error have been criticized for assuming detectable change is equivalent to important change [24, 36] . The comparison with other measures suggests that even small changes on the EASi-QoL domains may represent important change. Including reported change on the transition question or requiring change on more than one domain before defining a patient as having improved may add more certainty as to whether important change really occurred.
This study has several potential limitations. ES was used as the main measure of responsiveness so that the data from both studies could be directly compared. Other statistics [e.g. modified standardized response means (MSRM)] are often used to assess responsiveness to change. However, a recent review of different forms of response coefficients [37] suggests that ES may be the most appropriate measure. Calculation of comparative responsiveness with MSRM in this study resulted in similar results to evaluation by ES.
The observational cohort data have the potential to be affected by response bias arising from differences between responders and non-responders. Although no information is available regarding baseline non-responders, those who were not followed up were generally similar on baseline measures to those who were successfully followed up. The only differences were that responders at 6 months were slightly older and had slightly better EWB scores. These differences are unlikely to influence the results presented here. The study cohort was exclusively recruited from a secondary care sample, which may reflect a more severe presentation of AS than a communitybased sample and less severe disease than a cohort derived from tertiary care centres. However, the study population has similar demographics to those observed in other large AS studies conducted in the UK [10, 12] . Assessment of only patients showing improvement during the observational period of this non-interventional study restricted the patient numbers used in the MIC evaluation.
In the interventional trial, patients had to fulfil stringent inclusion criteria before participation. Therefore this cohort is not representative of patients normally seen in clinical practice.
ASAS indicated their recommendations should be revised in light of new evidence for the assessment of QoL. The EASi-QoL has proven acceptability, reliability and validity across a large and representative UK-wide sample. We have reported evidence of responsiveness following observational and intervention studies superior or similar to comparative disease-specific and generic measures. This is supplemented by evidence supporting score interpretation across the four health domains. The EASi-QoL should be considered for inclusion as the AS-specific measure of QoL amongst the core measures for AS.
Rheumatology key messages
. EASi-QoL has generally superior responsiveness levels in observational/trial situations compared with commonly used measures. . EASi-QoL may reflect important outcomes more accurately than other disease-specific or generic measures. . EASi-QoL captures the patient's perspective across four domains: PF, DA, EWB, SP.
